Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-15T18:30:36.075Z Has data issue: false hasContentIssue false
  • English
  • Français

FDG and Amyloid Positron Emission Tomography

Published online by Cambridge University Press:  07 November 2014

Mark A. Mintun
Mark A. Mintun*
Affiliation:
Dr. Mintun is professor of radiology with joint appointments in psychiatry, neurobiology and biomedical engineering; interim director of radiological science; director of the Center for Clinical Imaging Research; and director of the Division of Research Development, at, Washington University, School of Medicine in St. Louis, Missouri
Get accessRights & Permissions [Opens in a new window]

Extract

For over 20 years, researchers have used the tracer [18F]fluorodeoxyglucose (FDG) in positron emission tomography (PET) imaging. FDG PET imaging has been utilized to study the characteristic metabolic changes in Alzheimer’s disease (AD), and as more molecular imaging tracers become available for human research, PET will likely assume many new roles for investigating more specific abnormalities, such as amyloid deposition, in the future.

FDG is a glucose analog that images glucose metabolism and also illustrates neural firing. Different synapse activity, particularly excitatory activity from glutamate release, appears to change FDG uptake. AD will affect both brain infrastructure by decreasing the amount of cell bodies and synapses as well as decreasing synaptic activity, which are both changes that decrease the amount of FDG. AD is not a perfectly uniform process, and this is reflected by distinct progressive patterns of decreased FDG and decreased metabolism across different regions of the brain.

FDG enters the brain via blood flow, and then into brain tissue by both diffusion and facilitated transport. Once it enters the glia and neurons, FDG can be phosphorylated, a step that is essentially irreversible, but then cannot be processed further by the cells, effectively trapping the FDG in situ. The amount of trapping that occurs in the brain over the first 10–20 minutes is very high and constitutes over 80% of the uptake. Thus, after the first 10–20 minutes uptake phase, a pattern of FDG emerges that mirrors the distribution of glucose metabolism in all subcortical and cortical structures.

Information

Type
Research Article
Information
CNS Spectrums , Volume 13 , Issue S16 , 2008, pp. 21 - 24
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Mosconi, L, De Santi, S, Li, J, et al.Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008;29(5):676–692.Google Scholar
2.Reiman, EM, Caselli, RJ, Yun, LS, et al.Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752–758.CrossRefGoogle ScholarPubMed
3.Buckner, RL, Snyder, AZ, Shannon, BJ, et al.Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709–7717.Google Scholar
4.Silverman, DH, Small, GW, Chang, CY, et al.Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120–2127.CrossRefGoogle ScholarPubMed
5.Mosconi, L, Tsui, WH, Herholz, K, et al.Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390–398.Google Scholar
6.Klunk, WE, Engler, H, Nordberg, A, et al.Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.CrossRefGoogle ScholarPubMed
7.Mintun, MA, Larossa, GN, Sheline, YI, et al.[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–452.CrossRefGoogle Scholar
8.Nicoll, JA, Wilkinson, D, Holmes, C, Steart, P, Markham, H, Weller, RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9(4):448–452.Google Scholar
9.Price, JL, Morris, JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45(3):358–368.Google Scholar